BACKGROUND: Improved tests are needed for detection and management of prostate cancer. We hypothesized that differential gene expression in prostate tissue could help identify candidate blood biomarkers for prostate cancer and that blood from men with advanced prostate disease could be used to verify the biomarkers presence in circulation. METHODS: We identified candidate markers using mRNA expression patterns from laser-capture microdissected prostate tissue and confirmed tissue expression using immunohistochemistry (IHC) for the subset of candidates having commercial antisera. We analyzed tissue extracts with tandem mass spectrometry (MS/MS) and measured blood concentrations using immunoassays and MS/MS of trypsin-digested, immunoextracted peptides. RESULTS: We selected 35 novel candidate prostate adenocarcinoma biomarkers. For all 13 markers having commercial antisera for IHC, tissue expression was confirmed; 6 showed statistical discrimination between nondiseased and malignant tissue, and only 5 were detected in tissue extracts by MS/MS. Sixteen of the 35 candidate markers were successfully assayed in blood. Four of 8 biomarkers measured by ELISA and 3 of 10 measured by targeted MS showed statistically significant increases in blood concentrations of advanced prostate cancer cases, compared with controls. CONCLUSIONS: Seven novel biomarkers identified by gene expression profiles in prostate tissue were shown to have statistically significant increased concentrations in blood from men with advanced prostate adenocarcinoma compared with controls: apolipoprotein C1, asporin, cartilage oligomeric matrix protein, chemokine (C-X-C motif) ligand 11 (CXCL11), CXCL9, coagulation factor V, and proprotein convertase subtilisin/kexin 6.
BACKGROUND: Improved tests are needed for detection and management of prostate cancer. We hypothesized that differential gene expression in prostate tissue could help identify candidate blood biomarkers for prostate cancer and that blood from men with advanced prostate disease could be used to verify the biomarkers presence in circulation. METHODS: We identified candidate markers using mRNA expression patterns from laser-capture microdissected prostate tissue and confirmed tissue expression using immunohistochemistry (IHC) for the subset of candidates having commercial antisera. We analyzed tissue extracts with tandem mass spectrometry (MS/MS) and measured blood concentrations using immunoassays and MS/MS of trypsin-digested, immunoextracted peptides. RESULTS: We selected 35 novel candidate prostate adenocarcinoma biomarkers. For all 13 markers having commercial antisera for IHC, tissue expression was confirmed; 6 showed statistical discrimination between nondiseased and malignant tissue, and only 5 were detected in tissue extracts by MS/MS. Sixteen of the 35 candidate markers were successfully assayed in blood. Four of 8 biomarkers measured by ELISA and 3 of 10 measured by targeted MS showed statistically significant increases in blood concentrations of advanced prostate cancer cases, compared with controls. CONCLUSIONS: Seven novel biomarkers identified by gene expression profiles in prostate tissue were shown to have statistically significant increased concentrations in blood from men with advanced prostate adenocarcinoma compared with controls: apolipoprotein C1, asporin, cartilage oligomeric matrix protein, chemokine (C-X-C motif) ligand 11 (CXCL11), CXCL9, coagulation factor V, and proprotein convertase subtilisin/kexin 6.
Authors: N Leigh Anderson; Norman G Anderson; Lee R Haines; Darryl B Hardie; Robert W Olafson; Terry W Pearson Journal: J Proteome Res Date: 2004 Mar-Apr Impact factor: 4.466
Authors: Fabiola Cecchi; Chih-Jian Lih; Young H Lee; William Walsh; Daniel C Rabe; Paul M Williams; Donald P Bottaro Journal: Clin Exp Metastasis Date: 2015-08-01 Impact factor: 5.150
Authors: Paula J Hurley; Debasish Sundi; Brian Shinder; Brian W Simons; Robert M Hughes; Rebecca M Miller; Benjamin Benzon; Sheila F Faraj; George J Netto; Ismael A Vergara; Nicholas Erho; Elai Davicioni; R Jeffrey Karnes; Guifang Yan; Charles Ewing; Sarah D Isaacs; David M Berman; Jennifer R Rider; Kristina M Jordahl; Lorelei A Mucci; Jessie Huang; Steven S An; Ben H Park; William B Isaacs; Luigi Marchionni; Ashley E Ross; Edward M Schaeffer Journal: Clin Cancer Res Date: 2015-10-07 Impact factor: 12.531
Authors: Christine Levesque; Martin Fugère; Anna Kwiatkowska; Frédéric Couture; Roxane Desjardins; Sophie Routhier; Philippe Moussette; Adam Prahl; Bernard Lammek; Jon R Appel; Richard A Houghten; François D'Anjou; Yves L Dory; Witold Neugebauer; Robert Day Journal: J Med Chem Date: 2012-11-14 Impact factor: 7.446
Authors: Gvantsa Kharaishvili; Dana Simkova; Katerina Bouchalova; Mariam Gachechiladze; Nato Narsia; Jan Bouchal Journal: Cancer Cell Int Date: 2014-05-16 Impact factor: 5.722